[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intravitreal-injection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intravitreal-injection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100636608","effectiveness-of-multidisciplinary-protocolised-interventions-on-ivt-non-adherence-rates-100636608",false,"NCT07567898","Effectiveness of Multidisciplinary Protocolised Interventions on IVT Non-adherence Rates","The Effectiveness of Multidisciplinary Protocolised Interventions to Reduce Non-adherencE Rates (ADHERE) in Patients With Chronic Macula Diseases Receiving Intravitreal Injections: A Randomised Controlled Trial","ADHERE","Inclusion Criteria:\n\n* Patients with chronic macula disease including those diagnosed with nAMD and DME, who require IVT.\n* This would include treatment naive patients (no IVT in either eye the last 6 months) and previously treated patients who have had IVT in either eye in the last 6 months and require further IVT treatment at the baseline study visit in either eye.\n* Able to provide informed consent and must consent to undergoing the MPI intervention.\n* Speak English or Mandarin.\n* Must be a Singapore resident.\n\nExclusion Criteria:\n\n* Patients who are unwilling or unable to perform CAT testing.\n* Unable to provide informed consent.\n* Significant eye pathology such as cornea problems, glaucoma, or other retinal diseases that may substantially affect vision.\n* Do not speak English or Mandarin fluently.\n* Cognitive impairment (as assessed using 6CIT).\n* Obvious observable physical or hearing disabilities that prevents them from completing the CAT questionnaire and undergoing MPI effectively.","ALL",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this research study is to test whether a personalised care approach improves adherence compared to standard care. Many patients with macular diseases like age-related macular degeneration and diabetic macular edema need regular eye injections to protect their vision. However, some do not adhere to their treatment appointments, risking further vision loss.\n\nYou were selected as a possible participant in this research study because you have been diagnosed with neovascular age-related macular degeneration (nAMD) or diabetic macula edema (DME) requiring intravitreal injection treatment (IVT).\n\nThis research study targets to recruit 200 participants from the Singapore National Eye Centre.\n\nThis study comprises two cohort groups: Cohort 1(Suboptimal CAT scores\u002F Randomized Control trial) and Cohort 2 (Optimal CAT scores\u002FObservation).\n\nIf you agree to take part in this study, the research coordinator will obtain your written consent before proceeding with the study procedures. You will be required to complete CAT assessment (via remote or administered in clinic) and assigned to cohort 1 or cohort 2 based on CAT scores result. If you are assigned to cohort 1, you will be randomly allocated to either the personalized multi-disciplinary protocolized intervention (MPI) or standard care group. Randomization means assigning you to one of two groups by chance, like tossing a coin or rolling a dice.\n\n* MPI group: You will complete a specialized computerized adaptive testing (CAT) quality of life questionnaire. Based on the domain specific scores, you will receive a medical consultation and a referral to nurse educators, optometrists, occupational therapists, or social workers.\n* Standard care group: If you are allocated to this group, you will receive standard care, where doctors make treatment decisions without using the CAT results.\n\nIf you are assigned to cohort 2, you will be placed under prospective observation and undergo routine clinical care.",[26,27,28],"Diabetic Macular Edema","Neovascular (Wet) Age-Related Macular Degeneration","Intravitreal Injection",[30,31],"ADHERE, Macular diseases, Intravitreal injections.","neovascular age-related macular","NOT_YET_RECRUITING","2026-04-28",{"date":35,"type":36},"2026-05-05","ACTUAL",{"date":38,"type":20},"2026-04",{"date":40,"type":20},"2028-09",{"name":42,"class":43},"Singapore Eye Research Institute","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":5},"100616143","phase-4-comparing-single-versus-multiple-anti-vegf-injections-in-diabetic-patients-undergoing-cataract-surgery-100616143","NCT07301775","Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery","A Randomised Controlled Trial Comparing Efficacy of Single Versus Multiple Intravitreal Anti-VEGF Injections to Prevent Diabetic Retinopathy Progression in Patients Undergoing Cataract Surgery","Inclusion Criteria:\n\n* diabetic patients of both sexes ≥ 40 years of age presenting with non-proliferative diabetic retinopathy and cataract\n\nExclusion Criteria:\n\n* presence of proliferative diabetic retinopathy (PDR), diabetic macular oedema involving foveal centre, history of intraocular surgery or laser photocoagulation or prior anti-VEGF injection therapy in the study eye within past six months, history of intraocular inflammation (uveitis), glaucoma, mature cataract preventing satisfactory fundus examination preoperatively, poor glycaemic control (HbA1c\\>9%), pregnant and lactating women, known allergy to aflibercept (anti-VEGF used) and systemic thromboembolic events (stroke, myocardial infarction) within the last three months.","40 Years",{"count":53,"type":20},166,[55],"PHASE4","Objective of this randomised controlled trial is to compare the efficacy of a single per operative anti VEGF injection with repeated postoperative anti VEGF injections in the prevention of diabetic retinopathy progression after cataract surgery.\n\nThis Randomised Controlled Trial (RCT) will be conducted at Sahiwal Teaching Hospital and University College of Medicine \\& Dentistry Lahore. Duration of study will be from January 2026 to September 2026. This study will be single blind and parallel group research.\n\nThe study will include diabetic patients of both sexes ≥ 40 years of age presenting with non-proliferative diabetic retinopathy and cataract.\n\nExclusion criteria include proliferative diabetic retinopathy, center-involving diabetic macular oedema (DME), poor glycemic control (HbA1c \\>9%), glaucoma, uveitis, prior ocular surgery or laser, and recent systemic thromboembolic events.\n\nSubjects will be randomly divided into two groups, each containing 83 subjects. Standard phacoemulsification with intraocular lens implantation will be performed in all participants.\n\nA single intra vitreal Aflibercept injection ( 2mg\u002F0.05 ml ), will be given to group 1 participants. While, group 2 participants will receive an intra operative injection plus two additional injections at 1 month and 2 months postoperatively.\n\nFor all participants, follow up will be performed at 1 week, 1 month, 2 month, 3 month and 6 month.\n\nPrimary Outcome include progression of diabetic retinopathy (DR) severity (≥1 stage according to the guidelines of the international clinical diabetic retinopathy disease severity scale ICDR) or onset\u002Fprogression of DME.\n\nSecondary Outcomes include changes in best corrected visual acuity, changes in central macular thickness (CMT), and need for rescue treatment.\n\nSPSS version 26 will be utilised to analyse the data. P ≤ 0.05 will be taken as statistically significant. Qualitative variable like diabetic retinopathy grading and diabetic macular oedema status will be analysed by utilising Pearson's chi-square test. Quantitative variables like central macular thickness will be analysed by employing t-test.",[58,59,60,61,28],"Diabetic Retinopathy (DR)","Diabetic Macular Edema (DME)","Cataract","Phacoemulfisication+IOL Implantation",[63,64,65,28,66,67,68,69],"Vascular endothelial growth factor","Aflibercept","Cataract Extraction","Phacoemulsification","Diabetic retinopathy","Diabetic macular edema","Intraocular lens implantation","2025-12-10",{"date":72,"type":36},"2025-12-24",{"date":74,"type":20},"2026-01-01",{"date":76,"type":20},"2026-09-30",{"name":78,"class":43},"Ahmad Zeeshan Jamil"]